ACE2 and COVID-19: Following in-depth validation of the assay, we analyzed the IgG antibody response and ACE2 binding inhibition of 266 serum samples from 168 COVID-19 patients with mild to severe disease progression towards eleven different SARS-CoV-2 variant RBDs including the alpha, beta, gamma and delta VOCs.